Switching from TAF to TDF leads to weight loss
Switching from tenofovir alafenamide (TAF) to the older formulation of tenofovir disoproxil (TDF) resulted in modest weight loss in people with HIV in the Swiss HIV Cohort, researchers report in the journal Clinical Infectious Diseases. Switching from TAF to TDF also brought benefits in the forms of reduced cholesterol and triglycerides. In contrast, switching from TAF-containing treatment to a two-drug combination of dolutegravir/lamivudine or injectable cabotegravir/rilpivirine did not lead to any changes in weight.